Latest Ratings for EW
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | UBS | Upgrades | Neutral | Buy |
| Jan 2022 | Morgan Stanley | Maintains | Overweight | |
| Jan 2022 | Raymond James | Maintains | Outperform |
Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results
